OBJECTIVE: The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2. METHODS:A total of 179 patients were recruited and randomly assigned to one treatment group. Metabolic control (HbA1c), insulin resistance (HOMA index), and microvascular function (laser Doppler fluxmetry) were observed at baseline and after 3 and 6 months. RESULTS:HbA1c improved in both treatment arms (pioglitazone: 7.52 +/- 0.85% to 6.71 +/- 0.89%, p < .0001; glimepiride: 7.44 +/- 0.89% to 6.83 +/- 0.85%, p < .0001). Insulin-resistance decreased significantly in the pioglitazone group (6.15 +/- 4.05 to 3.85 +/- 1.92, p < .0001) and remained unchanged in the glimepiride group. The microvascular response to heat significantly improved in both treatment groups (pioglitazone 48.5 [15.2; 91.8] to 88.8 [57.6; 124.1] arbitrary units [AU], p < .0001; glimepiride 53.7 [14.1; 91.9] to 87.9 [52.9, 131.0] AU, p < .0001, median [lower and upper quartile]). Endothelial function as measured with the acetylcholine response improved in the pioglitazone group (38.5 [22.2; 68.0] to 60.2 [36.9; 82.8], p = .0427) and remained unchanged in the glimepiride group. CONCLUSIONS: Improving metabolic control has beneficial effects in microvascular function in type 2 diabetic patients. Treatment of type 2 diabetic patients withpioglitazone exerts additional effects on endothelial function beyond metabolic control.
RCT Entities:
OBJECTIVE: The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2. METHODS: A total of 179 patients were recruited and randomly assigned to one treatment group. Metabolic control (HbA1c), insulin resistance (HOMA index), and microvascular function (laser Doppler fluxmetry) were observed at baseline and after 3 and 6 months. RESULTS: HbA1c improved in both treatment arms (pioglitazone: 7.52 +/- 0.85% to 6.71 +/- 0.89%, p < .0001; glimepiride: 7.44 +/- 0.89% to 6.83 +/- 0.85%, p < .0001). Insulin-resistance decreased significantly in the pioglitazone group (6.15 +/- 4.05 to 3.85 +/- 1.92, p < .0001) and remained unchanged in the glimepiride group. The microvascular response to heat significantly improved in both treatment groups (pioglitazone 48.5 [15.2; 91.8] to 88.8 [57.6; 124.1] arbitrary units [AU], p < .0001; glimepiride 53.7 [14.1; 91.9] to 87.9 [52.9, 131.0] AU, p < .0001, median [lower and upper quartile]). Endothelial function as measured with the acetylcholine response improved in the pioglitazone group (38.5 [22.2; 68.0] to 60.2 [36.9; 82.8], p = .0427) and remained unchanged in the glimepiride group. CONCLUSIONS: Improving metabolic control has beneficial effects in microvascular function in type 2 diabeticpatients. Treatment of type 2 diabeticpatients with pioglitazone exerts additional effects on endothelial function beyond metabolic control.
Authors: Thomas Forst; Matthias M Weber; Michael Mitry; Thomas Schöndorf; Senait Forst; Mukadar Tanis; Andreas Pfützner; Georg Michelson Journal: J Diabetes Sci Technol Date: 2012-01-01
Authors: Jochen Wöhrle; Nikolaus Marx; Wolfgang Koenig; Vinzenz Hombach; Hans A Kestler; Martin Höher; Thorsten Nusser Journal: Clin Res Cardiol Date: 2008-04-24 Impact factor: 5.460
Authors: Michal Krčma; Daniela Cechurová; Jitka Brožová; Zdeněk Jankovec; Silvie Lacigová; Michal Zourek; Zdeněk Rušavý Journal: World J Diabetes Date: 2013-12-15
Authors: Andreas Pfützner; Alexander Weise; Elisabeth Pfützner-Riehn; Georg Lübben; Michael Morcos; Efstrathios Karagiannis; Matthias Weber; Thomas Forst Journal: PPAR Res Date: 2011-07-26 Impact factor: 4.964
Authors: Dimitrios Oikonomou; Stefan Kopf; Rüdiger von Bauer; Zdenka Djuric; Rita Cebola; Anja Sander; Stefan Englert; Spiros Vittas; Asa Hidmark; Michael Morcos; Grigorios Korosoglou; Peter P Nawroth; Per M Humpert Journal: Cardiovasc Diabetol Date: 2014-10-11 Impact factor: 9.951